Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
| Merck Sharp & Dohme LLC | INDUSTRY |
| Roche Pharma AG | INDUSTRY |
| Pfizer |
Not provided
Not provided
Not provided
Not provided
This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).
The database includes data related to patient demographics, tumor characteristics (diagnosis, histology, relapses, metastatic disease, etc.), treatments (dates, INN, route of administration, treatment protocols, reason for termination, etc.), and clinical events. Data is collected at each participating site by technicians who are specifically trained for the project using an electronic data collection (eDC) tool.
Data imported into the final database are controlled, recoded, and harmonized before import according to the data management plan. All coding procedures are predefined by the data manager. There is no transmission of individual data; all data are centralized within each center using a shared anonymous format. All data is exclusively obtained retrospectively; no attempts are made to recover non available data from the patient's medical record by contacting healthcare providers or patients.
ESME LC Data Platform aims to be a clinical and therapeutic database centralizing existing and available data from different sources used in the participating sites.
Data do not contain any personal data on patients. In compliance with the authorization delivered by the French Data Protection agency to Unicancer, only aggregated statistical reports and publication are released.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Patient characteristics | Age in years, Tobacco consumption, other exposures, Legal recognition as occupational disease, Medical history, History of other cancer, weight in kg and performance status (ECOG) | Baseline |
| Tumor characteristics | Staging, Tumor size, sampling Method, histological type | Baseline |
| Treatment patterns | Drug, therapeutic class, treatment duration at each n treatment line | From Baseline until 2024 (yearly basis) |
| Measure | Description | Time Frame |
|---|---|---|
| Median overall survival | Assessment of overall survival through treatment lines | From date of diagnosis or first treatment until the date of death from any cause. Follow up until 2024 |
| Median surrogate endpoints for overall survival |
Not provided
Inclusion criteria :
Exclusion criteria
- None
Not provided
Not provided
Not provided
All consecutive patients treated for lung cancer at one of the 38 French participating sites (Private comprehensive cancer centers and public hospitals).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lise Bosquet, MsC | Contact | 0033668642660 | l-bosquet@unicancer.fr | |
| Mathieu Robain, MD, PhD | Contact | 0033144235553 | m-robain@unicancer.fr |
| Name | Affiliation | Role |
|---|---|---|
| Anne-Laure Martin, Pharmacist | UNICANCER | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut de Cancérologie de l'Ouest - Paul Papin | Recruiting | Angers | 49933 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Robain M, Pérol M, Girard N, Debieuvre D, Coudert B, Madroszyk A, et al. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France. Revue des Maladies Respiratoires. 2018 Jan;35:A106. | ||
| Result | Girard, N., M. Pérol, G. Simon, C. Audigier Valette, R. Gervais, D. Debieuvre, R. Schott, et al. " 90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database ". Abstract Book of the European Lung Cancer Congress (ELCC) 10-13 April 2019, Geneva, Switzerland 30 (1 avril 2019): ii34. https://doi.org/10.1093/annonc/mdz067.006. | ||
| 34661827 | Result | Chouaid C, Filleron T, Debieuvre D, Perol M, Girard N, Dansin E, Lena H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hiret S, Pichon E, Clement-Duchene C, Chenuc G, Simon G, Bosquet L, QUantin X. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. Target Oncol. 2021 Nov;16(6):801-811. doi: 10.1007/s11523-021-00848-9. Epub 2021 Oct 18. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| INDUSTRY |
| Bristol-Myers Squibb | INDUSTRY |
| Janssen, LP | INDUSTRY |
| Amgen | INDUSTRY |
| Daiichi Sankyo | INDUSTRY |
| Pierre Fabre Medicament | INDUSTRY |
| Boehringer Ingelheim | INDUSTRY |
Not provided
Not provided
Not provided
Surrogate endpoints (Progression-free Survival, Time to Progression, Time to Next Treatment) at each n treatment line.
| From start date of the nth treatment line until the date of first applicable event. Follow up until 2024 |
| Institut Bergonié | Recruiting | Bordeaux | 33076 | France |
|
| Centre François Baclesse | Recruiting | Caen | 14076 | France |
|
| Centre Jean Perrin | Recruiting | Clermont-Ferrand | 63011 | France |
|
| Hôpital Intercommunal de Créteil | Recruiting | Créteil | 94000 | France |
|
| Centre Georges-François Leclerc | Recruiting | Dijon | 21079 | France |
|
| Centre Oscar Lambret | Recruiting | Lille | 59020 | France |
|
| Centre Léon Bérard | Recruiting | Lyon | 69373 | France |
|
| Institut Paoli-Calmettes | Recruiting | Marseille | 13273 | France |
|
| Institut régional du Cancer Montpellier / Val d'Aurelle | Recruiting | Montpellier | 34298 | France |
|
| Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller | Recruiting | Mulhouse | 68070 | France |
|
| Institut de cancérologie de l'Ouest - René Gauducheau | Recruiting | Nantes | 44805 | France |
|
| Centre Antoine Lacassagne | Recruiting | Nice | 06189 | France |
|
| Institut Curie | Recruiting | Paris | 75005 | France |
|
| Institut Jean Godinot | Recruiting | Reims | 51056 | France |
|
| Centre Henri Becquerel | Recruiting | Rouen | 76038 | France |
|
| Institut Curie - Hôpital René Huguenin | Recruiting | Saint-Cloud | 92210 | France |
|
| Centre Paul Strauss | Recruiting | Strasbourg | 67065 | France |
|
| Institut Claudius Regaud | Recruiting | Toulouse | 31059 | France |
|
| Institut de Cancérologie de Lorraine | Recruiting | Vandœuvre-lès-Nancy | 54519 | France |
|
| Institut Gustave Roussy | Recruiting | Villejuif | 94805 | France |
|
| 35008257 | Result | Lamy T, Cabarrou B, Planchard D, Quantin X, Schneider S, Bringuier M, Besse B, Girard N, Chouaid C, Filleron T, Simon G, Baldini C. Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers (Basel). 2021 Dec 24;14(1):92. doi: 10.3390/cancers14010092. |
| 36007281 | Result | Griesinger F, Perol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Janicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6. |
| 36551632 | Result | Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotte FE, Audigier-Valette C, Griesinger F. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers (Basel). 2022 Dec 13;14(24):6148. doi: 10.3390/cancers14246148. |
| 36657245 | Result | Bringuier M, Carton M, Debieuvre D, Pasquier D, Perol M, Filleron T, Lena H, Quantin X, Simon G, Baldini C. Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort. J Geriatr Oncol. 2023 Mar;14(2):101423. doi: 10.1016/j.jgo.2022.101423. Epub 2023 Jan 17. |
| 36652175 | Result | Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermon J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Adv Ther. 2023 Mar;40(3):1187-1203. doi: 10.1007/s12325-022-02408-7. Epub 2023 Jan 18. |
| 37311845 | Result | Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, Filleron T, Girard N, Schott R, Mathoulin-Pelissier S, Martin AL, Cousin S. Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting. Sci Rep. 2023 Jun 13;13(1):9584. doi: 10.1038/s41598-023-36623-1. |
| 37307617 | Result | Valette CA, Filleron T, Debieuvre D, Lena H, Perol M, Chouaid C, Simon G, Quantin X, Girard N. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy. Respir Med Res. 2023 Nov;84:101012. doi: 10.1016/j.resmer.2023.101012. Epub 2023 Mar 27. |
| 37339550 | Result | Heudel PE, de Montfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Filleron T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, Blay JY. Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2023 Aug;182:107280. doi: 10.1016/j.lungcan.2023.107280. Epub 2023 Jun 16. |
| 38833966 | Result | Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort. ESMO Open. 2024 Jun;9(6):103473. doi: 10.1016/j.esmoop.2024.103473. Epub 2024 Jun 3. |
| 39068144 | Result | Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Perol M, Bosquet L, Cabarrou B. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. J Geriatr Oncol. 2024 Sep;15(7):101819. doi: 10.1016/j.jgo.2024.101819. Epub 2024 Jul 26. |
| 39518004 | Result | Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X. Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights. Cancers (Basel). 2024 Oct 23;16(21):3563. doi: 10.3390/cancers16213563. |
| 40052124 | Result | Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Perol M. Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis. Front Oncol. 2025 Feb 20;15:1526931. doi: 10.3389/fonc.2025.1526931. eCollection 2025. |
| 40025432 | Result | Esnault C, Baschet L, Barbet V, Chenuc G, Perol M, Thokagevistk K, Pau D, Monnereau M, Bosquet L, Filleron T. Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer. BMC Med Res Methodol. 2025 Mar 1;25(1):57. doi: 10.1186/s12874-025-02500-w. |
| 40120335 | Result | Gobbini E, Diallo MH, Pasquier D, Schneider S, Chouaid C, Debieuvre D, Quantin X, Gervais R, Valette CA, Justeau G, Ravoire M, Madroszyk A, Pichon E, Falchero L, Simoneau Y, Bylicki O, Baranzelli A, Bosquet L, Perol M, Girard N. Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 2025 Apr;202:108499. doi: 10.1016/j.lungcan.2025.108499. Epub 2025 Mar 16. |
| 40262227 | Result | Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hulten A, Greystoke A. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 2025 May;203:108548. doi: 10.1016/j.lungcan.2025.108548. Epub 2025 Apr 19. |
| 41686417 | Result | Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Perol M. Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients. Adv Ther. 2026 Apr;43(4):1601-1621. doi: 10.1007/s12325-025-03465-4. Epub 2026 Feb 13. |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |